Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Key facts

Sponsor

Technische Universität Dresden

Intervention

Ivosidenib 250 MG (milligram)(drug)

Enrollment

76 enrolled

Eligibility

18-75 years · All sexes

Timeline

2025 – 2030

Study locations (12)

• Universitätsklinikum Aachen, Aachen, Germany
• Technische Universitaet Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
• Universitätsklinikum Essen, Essen, Germany
• Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany
• University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• Universitätsklinikum Jena, Jena, Germany
• Universitätsklinikum Schleswig-Holstein, Kiel, Germany
• Universität Leipzig, Leipzig, Germany
• Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), München, Germany
• Universität Münster, Münster, Germany
• Rostock University Medical Center, Rostock, Germany
• Universitaetsklinikum Ulm, Ulm, Germany

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myelodysplastic neoplasm with increased blasts

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07511829
  WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment
  University of Oxford
• RECRUITINGPHASE3NCT06499285
  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGPHASE1NCT06616636
  A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT06138587
  Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
  Dana-Farber Cancer Institute
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05782127
  Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
  Groupe Francophone des Myelodysplasies
• ACTIVE NOT RECRUITINGPHASE3NCT05949684
  ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
  Bristol-Myers Squibb
• ACTIVE NOT RECRUITINGPHASE2NCT04994808
  Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  Fred Hutchinson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT05379166
  Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
  Uma Borate

See all trials for Myelodysplastic neoplasm with increased blasts →